Loading cancer entity…
Loading cancer entity…
Clinical trials
126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 |
| clinicaltrials |
| NCT04960618 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | active not recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials